A toddler diagnosed with severe postinfectious bronchiolitis obliterans and COVID‐19 infection
| Autor: | Despina Mermiri, Patra Koletsi, Athanasios Michos, Dimitra Koukou, Vasiliki Spoulou, Marita Antoniadi, Georgia Koltsida, Maria Noni |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Pediatrics medicine.medical_specialty Bronchiolitis obliterans Context (language use) Risk Assessment Severity of Illness Index corticosteroids 03 medical and health sciences 0302 clinical medicine COVID‐19 030225 pediatrics antiviral agents Medicine Humans Toddler Letters to the Editor Child Asthma treatment business.industry Incidence (epidemiology) Compassionate Use Retrospective cohort study medicine.disease COVID-19 Drug Treatment 030228 respiratory system Pediatrics Perinatology and Child Health Compassionate Treatment business bronchiolitis obliterans |
| Zdroj: | Pediatric Pulmonology |
| ISSN: | 1099-0496 8755-6863 |
| Popis: | Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develop severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics.A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion.Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available.Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare cases of severe or critical disease, this guidance offers an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text